MDT

99.81

+3.15%↑

137.82

+0.03%↑

VEEV

218.82

-1.19%↓

HQY

84.51

-1.09%↓

NEOG

9.57

+1.7%↑

MDT

99.81

+3.15%↑

137.82

+0.03%↑

VEEV

218.82

-1.19%↓

HQY

84.51

-1.09%↓

NEOG

9.57

+1.7%↑

MDT

99.81

+3.15%↑

137.82

+0.03%↑

VEEV

218.82

-1.19%↓

HQY

84.51

-1.09%↓

NEOG

9.57

+1.7%↑

MDT

99.81

+3.15%↑

137.82

+0.03%↑

VEEV

218.82

-1.19%↓

HQY

84.51

-1.09%↓

NEOG

9.57

+1.7%↑

MDT

99.81

+3.15%↑

137.82

+0.03%↑

VEEV

218.82

-1.19%↓

HQY

84.51

-1.09%↓

NEOG

9.57

+1.7%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.11 -7.5

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1

Max

1.2

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+289.92% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-2.3M 123M
Eelmine avamishind	8.61
Eelmine sulgemishind	1.11

Uudiste sentiment

By Acuity

67%

33%

322 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. jaan 2026, 23:43 UTC

Market Talk

Gold Consolidates; May Face Technical Correction -- Market Talk

20. jaan 2026, 23:42 UTC

Market Talk

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20. jaan 2026, 23:41 UTC

Tulu

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20. jaan 2026, 23:29 UTC

Market Talk

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20. jaan 2026, 23:26 UTC

Market Talk

Global Equities Roundup: Market Talk

20. jaan 2026, 23:26 UTC

Market Talk

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20. jaan 2026, 22:45 UTC

Omandamised, ülevõtmised, äriostud

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20. jaan 2026, 22:45 UTC

Omandamised, ülevõtmised, äriostud

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20. jaan 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20. jaan 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20. jaan 2026, 22:27 UTC

Omandamised, ülevõtmised, äriostud

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20. jaan 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20. jaan 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20. jaan 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20. jaan 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20. jaan 2026, 22:18 UTC

Tulu

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20. jaan 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20. jaan 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20. jaan 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20. jaan 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20. jaan 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20. jaan 2026, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20. jaan 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20. jaan 2026, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20. jaan 2026, 22:07 UTC

Omandamised, ülevõtmised, äriostud

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20. jaan 2026, 22:06 UTC

Tulu

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20. jaan 2026, 22:00 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ESG Roundup: Market Talk

20. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

289.92% tõus

12 kuu keskmine prognoos

Keskmine 4.64 USD 289.92%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

322 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.